| Literature DB >> 29690549 |
Sergio Davinelli1, Michael E Nielsen2, Giovanni Scapagnini3.
Abstract
Astaxanthin, a xanthophyll carotenoid, is a secondary metabolite naturally synthesized by a number of bacteria, microalgae, and yeasts. The commercial production of this pigment has traditionally been performed by chemical synthesis, but the microalga Haematococcus pluvialis appears to be the most promising source for its industrial biological production. Due to its collective diverse functions in skin biology, there is mounting evidence that astaxanthin possesses various health benefits and important nutraceutical applications in the field of dermatology. Although still debated, a range of potential mechanisms through which astaxanthin might exert its benefits on skin homeostasis have been proposed, including photoprotective, antioxidant, and anti-inflammatory effects. This review summarizes the available data on the functional role of astaxanthin in skin physiology, outlines potential mechanisms involved in the response to astaxanthin, and highlights the potential clinical implications associated with its consumption.Entities:
Keywords: DNA repair; aging; anti-inflammatory; antioxidant; astaxanthin; clinical trials; immune-enhancing; skin; ultraviolet
Mesh:
Substances:
Year: 2018 PMID: 29690549 PMCID: PMC5946307 DOI: 10.3390/nu10040522
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Summary of human intervention studies on skin and astaxanthin.
| Intervention | Study Design | Control | Population ( | Duration | Outcomes | Dosage | Author, Year |
|---|---|---|---|---|---|---|---|
| Administration of ASX capsules | Randomized double-blind, controlled study | Placebo | Healthy female subjects (14/diet group) | 8 weeks | ↓ DNA damage biomarkers; | 2 or 8 mg | Park, 2010 |
| Administration of ASX capsules | Monitoring of oxidative stress and skin aging | None | 31 middle-aged volunteers | 4 weeks | ↓ MDA; | 4 mg | Chalyk, 2017 |
| Administration of ASX capsules | Randomized, double-blind, parallel-group, placebo-controlled | Placebo | 65 healthy female subjects | 16 weeks | ↓ Wrinkle parameters; | 6 or 12 mg | Tominaga, 2017 |
| Administration of ASX cream | Pilot study | None | 3 healthy female subjects | 2 weeks | ↓ Wrinkle parameters | 0.7 mg/g of ASX cream | Seki, 2001 |
| Topical application of ASX | Pilot study | None | 3 healthy male subjects | N/S | ↓ erythema | N/S | Yamashita, 1995 |
| Administration of ASX capsules | Randomized, single-blind, placebo-controlled | Placebo | 49 healthy female subjects | 6 weeks | ↓ Wrinkle parameters | 2 mg | Yamashita, 2006 |
| Oral and topical treatment with ASX | N/S | N/S | 28 healthy female subjects | 8 weeks | ↓ Wrinkle parameters | 6 mg | Tominaga, 2009 |
| Two oral forms (ASX capsules; tablets collagen) | Randomized, double-blind placebo-controlled | Placebo | 44 healthy female volunteers | 12 weeks | ↑ viscoelastic parameters; | 2 mg | Yoon, 2014 |
| Capsules of ASX combined with topical application of ASX | Open-label noncontrolled | None | 30 healthy female subjects | 8 weeks | ↓ wrinkles; | 6 mg and 2 mL (78.9 μM solution) | Tominaga, 2012 |
| Administration of ASX capsules | Randomized double-blind controlled | Placebo | 36 healthy male subjects | 6 weeks | ↓ wrinkles; | 6 mg | Tominaga, 2012 |
Abbreviations: ↑, increase; ↓, decrease; ASX, astaxanthin; NK, natural killer; IL-6, interleukin-6; MDA, malondialdehyde; RSSC, residual skin surface components; N/S, not specified; TEWL, transepidermal water loss; MMP, matrix metalloproteinase.